This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.

This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.

A guide for community leaders to use when planning to implement the “Talk. They Hear You.” campaign in their communities. The guide offers best practices and step-by-step guidance for using the campaign.

A guide for community leaders to use when planning events on underage drinking and substance use prevention for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for planning successful events.

A guide for community leaders to use when working with the media to promote underage drinking and substance use prevention resources for parents and caregivers, educators, and other adult role models. The guide offers best practices and sample materials for engaging the media.

This partner toolkit flash drive for the "Talk. They Hear You." Parent-Oriented National Media Campaign includes the full suite of products and supporting materials for use in communities.

This Advisory is an update to the SMA10-4591, Vol. 9 Issue 2, published in 2010. The advisory summarizes key elements of Traumatic Brain Injury (TBI), and describes its relevance to behavioral health, including recommendations for behavioral health professionals.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This report provides findings from a qualitative analysis of evidence-based and culturally relevant behavioral health practices offered at NNEDLearn, a SAMHSA training, offered from 2011 to 2020. It includes an overview of NNEDLearn, case studies, strategies and lessons learned, and conclusion.